BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 26898792)

  • 1. [KRAS mutation assay on EUS-FNA specimens from pacients with pancreatic mass].
    Bunganič B; Hálková T; Benešová L; Belšánová B; Laclav M; Hrůzová M; Traboulsi E; Frič P; Suchánek Š; Minárik M; Zavoral M
    Cas Lek Cesk; 2016; 155(1):48-51. PubMed ID: 26898792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with a KRAS mutation assay using allelic discrimination improves the diagnosis of pancreatic cancer.
    Bournet B; Selves J; Grand D; Danjoux M; Hanoun N; Cordelier P; Buscail L
    J Clin Gastroenterol; 2015 Jan; 49(1):50-6. PubMed ID: 24798941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS mutation testing on all non-malignant diagnosis of pancreatic endoscopic ultrasound-guided fine-needle aspiration biopsies improves diagnostic accuracy.
    Trisolini E; Armellini E; Paganotti A; Veggiani C; Bozzola C; Frattini M; Pizio C; Mancuso G; Andorno S; Boldorini R
    Pathology; 2017 Jun; 49(4):379-386. PubMed ID: 28450086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with KRAS mutation assay to distinguish pancreatic cancer from pseudotumoral chronic pancreatitis.
    Bournet B; Souque A; Senesse P; Assenat E; Barthet M; Lesavre N; Aubert A; O'Toole D; Hammel P; Levy P; Ruszniewski P; Bouisson M; Escourrou J; Cordelier P; Buscail L
    Endoscopy; 2009 Jun; 41(6):552-7. PubMed ID: 19533561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS mutation analysis of washing fluid from endoscopic ultrasound-guided fine needle aspiration improves cytologic diagnosis of pancreatic ductal adenocarcinoma.
    Park JK; Lee YJ; Lee JK; Lee KT; Choi YL; Lee KH
    Oncotarget; 2017 Jan; 8(2):3519-3527. PubMed ID: 27974679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer.
    Salek C; Benesova L; Zavoral M; Nosek V; Kasperova L; Ryska M; Strnad R; Traboulsi E; Minarik M
    World J Gastroenterol; 2007 Jul; 13(27):3714-20. PubMed ID: 17659731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Native Aspirates and Cytological Smears Obtained by EUS-Guided Biopsies for Effective DNA/RNA Marker Testing in Pancreatic Cancer.
    Benesova L; Halkova T; Bunganic B; Belsanova B; Zavoral M; Traboulsi E; Minarik M
    Pathol Oncol Res; 2020 Jan; 26(1):379-385. PubMed ID: 30361898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of K-ras gene mutation analysis in EUS-guided FNA cytology specimens for the differential diagnosis of pancreatic solid masses: a meta-analysis of prospective studies.
    Fuccio L; Hassan C; Laterza L; Correale L; Pagano N; Bocus P; Fabbri C; Maimone A; Cennamo V; Repici A; Costamagna G; Bazzoli F; Larghi A
    Gastrointest Endosc; 2013 Oct; 78(4):596-608. PubMed ID: 23660563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of KRAS gene mutations in endoscopic ultrasound-guided fine-needle aspiration biopsy for improving pancreatic cancer diagnosis.
    Wang X; Gao J; Ren Y; Gu J; Du Y; Chen J; Jin Z; Zhan X; Li Z; Huang H; Lv S; Gong Y
    Am J Gastroenterol; 2011 Dec; 106(12):2104-11. PubMed ID: 21876563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. K-ras mutation analysis of residual liquid-based cytology specimens from endoscopic ultrasound-guided fine needle aspiration improves cell block diagnosis of pancreatic ductal adenocarcinoma.
    Sekita-Hatakeyama Y; Nishikawa T; Takeuchi M; Morita K; Takeda M; Hatakeyama K; Nakai T; Uchiyama T; Itami H; Fujii T; Mitoro A; Sho M; Ohbayashi C
    PLoS One; 2018; 13(3):e0193692. PubMed ID: 29494669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors.
    Berry W; Algar E; Kumar B; Desmond C; Swan M; Jenkins BJ; Croagh D
    Int J Cancer; 2017 May; 140(10):2331-2343. PubMed ID: 28198009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Droplet digital polymerase chain reaction detection of KRAS mutations in pancreatic FNA samples: Technical and practical aspects for routine clinical implementation.
    Mansour Y; Boubaddi M; Odion T; Marty M; Belleannée G; Berger A; Subtil C; Laurent C; Dabernat S; Amintas S
    Cancer Cytopathol; 2024 May; 132(5):274-284. PubMed ID: 38308613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of K-ras mutation analysis in EUS-guided FNA specimens from pancreatic masses.
    Ogura T; Yamao K; Sawaki A; Mizuno N; Hara K; Hijioka S; Niwa Y; Tajika M; Kondo S; Shimizu Y; Bhatia V; Higuchi K; Hosoda W; Yatabe Y
    Gastrointest Endosc; 2012 Apr; 75(4):769-74. PubMed ID: 22284089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS Mutation Testing on Endoscopic Ultrasound-Guided Fine-Needle Aspiration Samples Improves the Diagnostic Accuracy of Pancreatic Cancer.
    Yeung MCF; Shek TWH
    Pancreas; 2022 Nov-Dec 01; 51(10):1365-1371. PubMed ID: 37099780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Local Recurrence of Pancreatic Cancer by KRAS Mutation Analysis Using Washes from Endoscopic Ultrasound-Guided Fine-Needle Aspiration.
    Matsumoto K; Kato H; Nouso K; Ako S; Kinugasa H; Horiguchi S; Saragai Y; Takada S; Yabe S; Muro S; Uchida D; Tomoda T; Okada H
    Dig Dis Sci; 2020 Oct; 65(10):2907-2913. PubMed ID: 31897893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic and Prognostic Values of KRAS Mutations on EUS-FNA Specimens and Circulating Tumor DNA in Patients With Pancreatic Cancer.
    Wang R; Zhao Y; Wang Y; Zhao Z; Chen Q; Duan Y; Xiong S; Luan Z; Wang J; Cheng B
    Clin Transl Gastroenterol; 2022 May; 13(5):e00487. PubMed ID: 35351843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
    Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
    Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Impact of KRAS and GNAS Analysis Added to CEA and Cytology in Pancreatic Cystic Fluid Obtained by EUS-FNA.
    Faias S; Duarte M; Albuquerque C; da Silva JP; Fonseca R; Roque R; Dias Pereira A; Chaves P; Cravo M
    Dig Dis Sci; 2018 Sep; 63(9):2351-2361. PubMed ID: 29796909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS mutation analysis by next-generation sequencing in endoscopic ultrasound-guided sampling for solid liver masses.
    Choi HJ; Moon JH; Kim HK; Lee YN; Lee TH; Cha SW; Cho YD; Park SH
    J Gastroenterol Hepatol; 2017 Jan; 32(1):154-162. PubMed ID: 27118240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FNA smears of pancreatic ductal adenocarcinoma are superior to formalin-fixed paraffin-embedded tissue as a source of DNA: Comparison of targeted KRAS amplification and genotyping in matched preresection and postresection samples.
    Hartley CP; Mahajan AM; Selvaggi SM; Rehrauer WM
    Cancer Cytopathol; 2017 Nov; 125(11):838-847. PubMed ID: 29024530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.